Ozempic Lawsuit Latest Updates in Two MDLs (2026)

Sarah Edwards's profile picture

Sarah Edwards

Contributor

Adam Ramirez, J.D.'s profile picture

Reviewed ByAdam Ramirez, J.D.

Editor

Read in 13mins

Litigation Active – Ozempic Cases Are Still Pending

Status: Active – expert-challenge stage in the stomach injury MDL, early discovery in the vision loss MDL, no settlement announced

Docket: MDL No. 3094 – In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation; MDL No. 3163 – In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation

Court: U.S. District Court for the Eastern District of Pennsylvania – Judge Karen S. Marston

Pending cases: 4,082 in MDL 3094 and 278 in MDL 3163 (JPML, as of November 2, 2026)

Next key date: No trial date set

Article Summary

  • Ozempic claims are now split into two federal MDLs
  • The vision loss MDL is in early discovery, and neither MDL has a trial date
  • Filing deadlines vary by state, so it's important to act promptly

Ozempic has been in the news recently as a popular anti-obesity drug.

But it has also made news for potentially dangerous side effects such as gallbladder disease and gastroparesis, a weakening of the stomach that can lead to stomach pain and vomiting. Those are just two of several serious symptoms. Other symptoms include potentially fatal issues like intestinal blockages and other severe health problems.

Those pursuing semaglutide lawsuits state that the manufacturers didn’t issue adequate warnings and information about risks. They state that if they had known about the risks of Ozempic and other semaglutide drugs, they may not have used them. Now, Ozempic lawsuits against Ozempic are springing up around the country.

Free Ozempic Lawsuit Case Review!

0/2000

Mentioned by

CBSCNNFOXNew York Times

Major Developments in the Lawsuit History

  • October 20, 2026: Judge Marston ordered every plaintiff in the vision loss MDL to fill out a fact sheet about their drug use and injury.
  • December 15, 2025: The JPML, a federal panel that groups similar cases, created MDL No. 3163 for claims that Ozempic and other GLP-1 drugs caused NAION, a sudden and permanent vision loss.
  • October 14, 2025: The FDA expanded Ozempic's warning on severe stomach side effects and added intestinal obstruction and acute kidney injury to its reported reactions.
  • August 15, 2025: Judge Marston ruled that plaintiffs claiming gastroparesis, or slowed stomach emptying, must prove it with a properly done gastric emptying test.
  • February 2, 2024: The JPML grouped federal cases over stomach and bowel injuries into MDL No. 3094 in Pennsylvania, covering Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro.
Following the case

Full Ozempic Lawsuit Updates Timeline (2017–2026)

40 updates
  1. Court Sets Fact Sheet Rules for Vision Loss Cases

    Judge Karen Spencer Marston entered Case Management Order No. 16 in MDL 3163, the federal NAION vision loss MDL. Every plaintiff must fill out a plaintiff fact sheet, a standard questionnaire about drug use and injury, and sign forms that let both sides gather medical records through one shared vendor. Plaintiffs later chosen for the bellwether pool may need to complete a supplemental fact sheet.

  2. Closing Arguments Heard on Expert Challenges in Gastrointestinal MDL

    In MDL 3094, the gastrointestinal injury MDL, lawyers gave closing arguments on the pending Rule 702 motions for Cross Cutting Issues 2 and 3. Rule 702 motions ask a judge to bar expert testimony that is not reliable. Here, the experts address warning adequacy and preemption, and whether GLP-1 drugs can cause the alleged injuries at all. The session carried over to October 14.

  3. Five-Day Expert Hearing Held in Gastrointestinal MDL

    Judge Marston opened a five-day evidentiary hearing on the motions to exclude expert opinions for Cross Cutting Issues 2 and 3. Issue 2 asks whether federal law blocks the failure-to-warn claims or whether the warnings were adequate. Issue 3 asks whether the drugs can cause the alleged gastrointestinal injuries in general. The hearing ended September 18.

Show 37 earlier updates
  1. Vision Loss MDL Schedule Set Into 2027

    Case Management Order No. 14 set the early schedule in the NAION MDL. Plaintiffs had until October 28, 2026, to file a master complaint. Fact discovery on general causation and preemption/warning adequacy was set to close December 18, 2026, for Lilly and February 26, 2027, for Novo Nordisk. Motions to exclude experts and summary judgment motions were due July 2, 2027, with final replies due August 31, 2027.

  2. Special Discovery Master Named in Vision Loss MDL

    The court appointed a special master for discovery in the NAION MDL: retired Judge Lawrence F. Stengel. A special master is a court-appointed officer who helps resolve discovery disputes. Stengel has held the same role in the gastrointestinal MDL since July 2024.

  3. NAION MDL Will Tackle Causation and Preemption First

    Siding with the defense, Judge Marston ordered early discovery and motions in the NAION MDL on two issues: general causation (whether the drugs can cause NAION at all) and preemption/warning adequacy. She noted that as of June 15, 2026, only 19 of 137 cases named the Lilly defendants. Marketing discovery and plaintiff fact sheets were to move forward at the same time, so bellwether picks could follow quickly if needed.

  4. New Jersey Judge Appoints Leaders for State NAION Cases

    In the New Jersey state court NAION litigation, Bergen County master docket BER-L-3317-26, Judge Gregg A. Padovano named plaintiffs' lead counsel: Ellen Relkin of Weitz & Luxenberg and Adam Slater of Mazie Slater Katz & Freeman. A separate order the same day named defense lead counsel. His initial case management order had issued April 13, 2026.

  5. Court Holds Science Day in NAION MDL

    The court held Science Day in the NAION MDL. Under a March 16, 2026 scheduling order, each side had about 2.5 hours to walk the judge through GLP-1 drugs, their labeling history, the eye, and the medical literature on NAION in an objective format. Individual plaintiffs and sales practices were off-limits, and the transcript and slides cannot be used as evidence.

  6. Court Rejects Lilly Bid to Narrow Kessler Expert Opinions

    Judge Marston denied Lilly's motion to hold plaintiffs' expert Dr. David Kessler to what his January 2, 2026 report disclosed. Her written memorandum found the report gave fair notice of the disputed opinions, including that a 2022 Lilly dulaglutide safety report to the FDA reached flawed conclusions. Plaintiffs agreed to use only opinions in the report, and Lilly could confer about more deposition time.

  7. Fifth Amended Schedule Sets Fall 2026 Expert Hearing

    At Novo Nordisk's unopposed request, the court issued a fifth amended schedule for Cross Cutting Issues 2 and 3 in MDL 3094. Motions to exclude experts and summary judgment motions were due May 19, 2026, and the last replies were due August 7, 2026. A hearing on the expert motions was set for September 10 to 18, 2026. That day, the judge also amended the fact sheet order every plaintiff must follow.

  8. FDA Warning Letter Cites Novo's Side Effect Reporting

    The FDA's drug center sent Novo Nordisk Inc. a warning letter over how it handled side effect reports for products including semaglutide, the active drug in Ozempic. After a January to February 2025 inspection, the agency said some serious reports, such as reported deaths and a suicide, reached the FDA late or never. It said the failures pointed to systemic problems in the company's safety monitoring.

  9. Leadership Team Named for Vision Loss MDL

    Case Management Order No. 5 named Parvin Aminolroaya (Seeger Weiss), Jonathan D. Orent (Motley Rice), and Sarah Ruane (Wagstaff & Cartmell) as plaintiffs' co-lead counsel in the NAION MDL, along with an executive committee and two liaison counsel. For now, the judge declined a defense request to stop leadership lawyers from filing qualifying cases in state court.

  10. Direct Filing Allowed in Vision Loss MDL

    Under a stipulated direct filing order, plaintiffs whose NAION cases would be sent to the MDL could file them straight into the Pennsylvania MDL court. This avoids the delay of suing in another federal court and waiting for a transfer. The order also set up simpler service on the defendants.

  11. First Orders Issued in New NAION MDL

    Judge Marston's first case management order in MDL 3163 paused response deadlines and discovery in the transferred cases and asked each side for a short statement of the key facts and legal issues. It set the first conference for January 13, 2026, which went ahead as planned.

  12. Separate Federal MDL Created for GLP-1 Vision Loss

    The JPML, the federal panel that groups similar cases, created MDL No. 3163 for claims that Ozempic, Wegovy, Saxenda, or Trulicity caused NAION, a condition that brings sudden, permanent vision loss. It began with 21 actions in three districts. The panel picked Judge Marston in Pennsylvania over the New Jersey court plaintiffs wanted, but declined Lilly's request to merge the cases into MDL 3094, saying a separate MDL would make tracking easier.

  13. New Jersey Creates Two State GLP-1 Mass Torts

    The New Jersey Supreme Court designated two separate multicounty litigations, New Jersey's version of an MDL, for state cases that name Lilly and Novo Nordisk: one for gastrointestinal injuries and one for NAION vision loss. Both cover Ozempic and five other GLP-1 drugs and went to Judge Gregg A. Padovano in Bergen County. The court announced the orders in a November 10, 2025 notice.

  14. FDA Updates Ozempic's Severe Gastrointestinal Warning

    The FDA approved label changes that expanded the Severe Gastrointestinal Adverse Reactions warning for Ozempic to say such reactions have also been reported with GLP-1 drugs after approval. The update also added intestinal obstruction, severe constipation with fecal impaction, and acute kidney injury to the list of side effects reported after the drug reached the market.

  15. Short Form Complaints Adopted in Gastrointestinal MDL

    Plaintiffs filed an amended master complaint on August 29, 2025, after the dismissal ruling. Then Case Management Order No. 27 made that master complaint plus each plaintiff's short form complaint the operative pleading. A short form complaint is a fill-in form that adopts the shared claims and adds case details. Defendants had 60 days to respond to the master complaint.

  16. FDA Faults Novo Over Oprah TV Special

    The FDA sent Novo Nordisk a warning letter about an ABC prime-time Oprah special on weight loss drugs that first aired March 18, 2024, and featured paid Novo consultants and a Novo sales executive. The agency found the program false or misleading, said it misbranded Wegovy, Ozempic, and Victoza, and said it gave a misleading impression of the drugs' safety.

  17. Gastroparesis Claims Now Require a Gastric Emptying Test

    After a May 14, 2025 evidentiary hearing, Judge Marston excluded the opinions of plaintiffs' experts Drs. Daniel Raines and Eliot Siegel on Cross Cutting Issue 1. A plaintiff claiming gastroparesis (slowed stomach emptying) must prove the diagnosis came from a gastric emptying test that was done correctly, such as scintigraphy, a breath test, or a wireless motility capsule. Her written opinion said most plaintiffs allege lasting gastroparesis.

  18. Court Trims but Keeps Key Claims in Master Complaint

    Ruling on the defense motion to dismiss, Judge Marston let the express and implied warranty claims and the negligent undertaking claim go forward, along with fraud claims tied to what the FDA-approved labels left out. Design defect, general negligence, intentional misrepresentation, consumer protection, and medical monitoring claims were dismissed with leave to amend. Her 79-page opinion explains each ruling.

  19. Saxenda Added to MDL, Blood Clot Cases Kept Out

    The JPML added Saxenda, a sixth GLP-1 drug made by Novo Nordisk, to MDL 3094 for gastrointestinal injury claims. In a separate order that day, it refused to widen the MDL to cover deep vein thrombosis, pulmonary embolism, and other blood clot injuries. The panel warned that an MDL covering every possible injury from these drugs could become unwieldy.

  20. Plaintiffs File Master Complaint in Gastrointestinal MDL

    Plaintiffs filed their master long form complaint, one pleading that sets out the common allegations against both drugmakers. As the court later summarized it, the complaint had 17 counts, including warranty, fraud, design defect, negligence, wrongful death, and loss of consortium claims, and sought economic, noneconomic, and punitive damages.

  21. FDA Adds Pulmonary Aspiration Warning to Ozempic

    The FDA approved new Ozempic labeling on the serious risk of pulmonary aspiration, when stomach contents get into the lungs, in patients having elective surgery or procedures under general anesthesia or deep sedation. The change followed a September 6, 2024 FDA letter saying this new safety information belonged in the labeling of GLP-1 drugs.

  22. Schedule Set for Preemption and Causation Issues

    Case Management Order No. 20 set deadlines for Cross Cutting Issues 2 and 3. The parties agreed Issue 3, general causation, would cover gastroparesis, ileus, small bowel obstruction, and gallbladder injuries. Fact discovery was to end July 2, 2025, with motions to exclude experts due October 27, 2025, and summary judgment motions due two days later. These dates were later extended.

  23. Judge Denies Early Marketing Discovery

    Judge Marston denied plaintiffs' motion to open discovery into the drugmakers' marketing during the early phase. Her written memorandum said marketing to doctors was not needed to decide preemption and warning adequacy. She warned the defendants they could not hold back relevant documents just by labeling them marketing.

  24. Court Fast-Tracks Shared Issues in Gastrointestinal MDL

    In Case Management Order No. 18, Judge Marston granted the defense request for early discovery and motions on two issues common to all cases: how gastroparesis must be diagnosed, and whether federal law preempts the failure-to-warn claims or the warnings were adequate. She put off deciding on a third issue, general causation, until more briefing.

  25. Special Discovery Master Appointed in Gastrointestinal MDL

    Under Case Management Order No. 16, the court appointed retired Judge Lawrence F. Stengel as special discovery master in MDL 3094. He was given the power to manage discovery disputes, including those with outside parties, at a rate of $1,000 per hour.

  26. Blood Clot Cases Paused Pending Panel Decision

    The court stayed two direct-filed cases, Ulrich and Shirley, that alleged venous thromboembolism, a type of blood clot. Judge Marston noted that the JPML had defined the shared injuries as gastrointestinal, so the parties needed the panel's approval before adding a new injury type to the MDL.

  27. Claims Against Nine Extra Novo Entities Dropped

    Based on a stipulation, Case Management Order No. 13 dismissed without prejudice the claims against nine related companies, including Novo Nordisk North America Operations A/S and Emisphere Technologies. Only Novo Nordisk A/S and Novo Nordisk Inc. remained as Novo defendants. If the stipulation were vacated, plaintiffs could add the dropped entities back as if named from the start.

  28. Direct Filing Order Entered in Gastrointestinal MDL

    Judge Marston signed a direct filing order letting plaintiffs file qualifying cases straight into MDL 3094 in Pennsylvania federal court, rather than suing in another federal court and waiting for a transfer. The order also streamlined service on the defendants.

  29. MDL Reassigned to Judge Marston After Judge Pratter's Death

    Gene E.K. Pratter, the first judge on MDL 3094, died in May 2024, and the Eastern District of Pennsylvania posted a tribute on May 17 calling her passing a tremendous loss for the court. Citing her death, the JPML reassigned the litigation to Judge Karen S. Marston of the same court. Marston then scheduled her first status conference in the MDL for June 10, 2024.

  30. Plaintiffs' Co-Lead Counsel Appointed

    Judge Pratter's Case Management Order No. 6 named four plaintiffs' co-lead counsel: Paul Pennock (Morgan & Morgan), Parvin Aminolroaya (Seeger Weiss), Sarah Ruane (Wagstaff & Cartmell), and Jonathan D. Orent (Motley Rice). The order also created an executive committee with posts covering trial strategy, science, marketing discovery, and bellwether selection.

  31. Plaintiffs' Committee and Liaison Counsel Named

    In Case Management Order No. 3, Judge Pratter named Roberta Liebenberg and Nina Spizer as plaintiffs' liaison counsel and appointed an eight-lawyer plaintiffs' committee. The committee could add members, up to a total of 25.

  32. Federal GLP-1 MDL Created in Pennsylvania

    The JPML ordered the cases centralized as MDL No. 3094 in Pennsylvania's Eastern District before Judge Gene E.K. Pratter. It covered gastrointestinal injury claims over Novo Nordisk's Ozempic, Wegovy, and Rybelsus and Eli Lilly's Trulicity and Mounjaro, rejecting arguments to leave Lilly out. The motion involved 18 actions in 11 districts plus 37 related cases, and the chosen district already had 13 of those 55.

  33. Danish Parent Company Kept in Early Ozempic Case

    In the Bjorklund case, Judge James D. Cain Jr. denied the motion by Novo Nordisk A/S and Novo Nordisk North America Operations A/S to dismiss for lack of personal jurisdiction, so the court could hear claims against them. He dismissed the express warranty claim against those two companies with prejudice, which means it cannot be refiled.

  34. Early Ozempic Gastroparesis Case Survives Dismissal Bids

    In Jaclyn Bjorklund's Louisiana federal case over Ozempic and Mounjaro, Judge Cain granted only part of the U.S. Novo Nordisk companies' motion to dismiss, cutting her express warranty claim with leave to amend and keeping the rest. On December 11, he ruled the same way on Eli Lilly's motion. She alleged the drugs caused gastroparesis.

  35. FDA Adds Ileus to Ozempic Label

    The FDA approved a label update adding ileus, a condition where the intestines stop moving food along, to the side effects reported for Ozempic after it reached the market. Ileus later became one of the injuries at issue in MDL 3094.

  36. Gallbladder Disease Warning Added to Ozempic Label

    The Ozempic label approved in March 2022 listed acute gallbladder disease as a newly added warning. It told doctors to order gallbladder studies if gallstones or gallbladder inflammation were suspected. The FDA approved this labeling with its March 28, 2022 letter for a new 2 mg dose.

  37. FDA Approves Ozempic

    The FDA approved Ozempic (semaglutide) injection from Novo Nordisk to improve blood sugar control for adults who have type 2 diabetes, used along with diet and exercise.

Do I Qualify for

Ozempic Lawsuit Compensation?
Free Case Review→

Ozempic Lawsuit Updates and News

The past few months have significantly shaped the direction of the Ozempic lawsuits. Although it’s too early to start discussing lawsuit settlements, these new developments may have permanently changed the course of the litigation.

There have been no settlements in either MDL. Moreover, the number of cases continues to increase as more patients start using GLP-1 medications and those already on the medications begin to suffer adverse effects.

The possible link between vision loss and Ozempic has driven lawyers to seek plaintiffs who suffered this injury but may not have connected it to their use of GLP-1 medication.

Judge Marston Clarified the Rules for Gastroparesis Claims

On August 15, 2025, Judge Karen Spencer Marston issued a ruling that narrowed the pool of plaintiffs. She said that any patient making a claim involving gastroparesis must be able to prove the diagnosis involved a gastric emptying study.

This ruling has the obvious downside of denying legitimately injured plaintiffs compensation because they didn’t have a particular diagnostic test. However, it does have one advantage: plaintiffs now have a clearer idea of the evidence needed to be successful.

Stomach Injury MDL: Expert Challenges Heard

Judge Marston held a five-day evidentiary hearing from September 14 to 18, 2026. The hearing focused on motions filed to exclude expert opinions in the MDL for stomach injuries.

The expert had to address two main questions: whether the warnings were adequate or federal law blocks failure-to-warn claims, along with whether GLP-1 medications cause the alleged gastrointestinal injuries. Closing arguments occurred on October 13 and 14, 2026. The motions are all still pending. No trial dates have been set.

NAION Vision Loss Cases Now Have Their Own Federal MDL

Vision loss claims are increasing in number and focus on non-arteritic anterior ischemic optic neuropathy (NAION). It’s a rare condition that causes irreversible vision loss. The New Jersey Supreme Court created a state mass tort for these cases on October 16, 2025. The mass tort is overseen by Judge Gregg A. Padovano, out of Bergen County.

Growing evidence suggests that Ozempic and other GLP-1s can cause NAION. In October 2025, the American Academy of Ophthalmology issued a press release indicating that people taking GLP-1s were 68.6 times more likely to develop NAION than people taking empagliflozin, metformin and other common diabetes treatments.

The Judicial Panel on Multidistrict Litigation created MDL No. 3163 in December 2025. The MDL covers claims stating that Ozempic, Saxenda, Wegovy and Trulicity cause NAION. Although plaintiffs would have preferred a New Jersey court, the panel decided on a Pennsylvania court overseen by Judge Marston. The court declined to merge these vision cases with the MDL for stomach injuries.

Judge Marston ordered early discovery on whether the medications can result in NAION, along with whether federal law preempts failure-to-warn claims or the warnings were sufficient. If the court respects the current schedule, summary judgment motions and motions to exclude experts are due by July 2, 2027.

What Is the Ozempic Class Action Lawsuit?

Ozempic is a medication widely used for the treatment of type 2 diabetes and, more recently, as an off-label weight loss treatment. Patients later suffered gastrointestinal conditions from using it.

The serious side effects seem widespread. However, claims are not being handled in Ozempic class action lawsuits. Instead, there are cases that the court has combined into two federal multidistrict litigations (MDLs). MDL No. 3094 is for bowel and stomach injuries, while MDL No. 3163 is for NAION vision loss.

An MDL is different in that people can pursue individual settlements and verdicts rather than take a piece of a class settlement. It streamlines proceedings and prevents conflicting rulings from judges.

The 4,082 pending lawsuits in November 2026 allege ileus, gastroparesis, intestinal blockage and other serious injuries. The Eastern District of Pennsylvania manages these cases as part of MDL No. 3094.

Plaintiffs argue that Novo Nordisk, the manufacturer of Ozempic, didn’t adequately warn patients and healthcare providers about these potential risks. This echoes claims in similar lawsuits, such as the Gardasil lawsuit, where plaintiffs argue that Merck failed to adequately warn users about the Gardasil vaccine’s long-term side effects. Attorneys are also researching other potential claims after a study in JAMA Ophthalmology found a link between semaglutide (Ozempic’s active ingredient) and vision loss.

There have been no publicly reported Ozempic lawsuit settlement amounts so far.

Do I Qualify for

Ozempic Lawsuit Compensation?
Free Case Review→

Broadly speaking, the claims against Ozempic fall into two categories: Product liability and misrepresentation.

Product Liability

Product liability cases involve manufacturers who market faulty or dangerous products. Usually, these are strict liability cases, meaning that the manufacturer can be held liable for dangerous products even if it wasn’t negligent.

Misrepresentation

Most claims involved in the Ozempic MDL also allege that Novo Nordisk deliberately misrepresented the drug, downplaying its dangers and overly emphasizing its benefits.

How the Court Ruled on the Master Complaint

Judge Marston ruled on the defense’s motion to dismiss on August 15, 2025. The judge allowed the negligent undertaking claim and the express and implied warranty claims to move forward, together with fraud claims involving what the labels that the FDA approved left out.

Judge Marston, however, dismissed claims of intentional misrepresentation, general negligence, design defect, consumer protection and medical monitoring. She dismissed them with leave to amend. On August 29, 2025, plaintiffs filed an amended master complaint.

Ozempic Cases on the Rise

When the Ozempic MDL started in February 2024, it had 55 lawsuits. In November 2026, there were 4,082 pending cases. This number is expected to spike as Ozempic use continues to increase.

Also, a study discovered that healthcare providers wrote over 9 million prescriptions for Ozempic and similar drugs containing semaglutide during the last three months of 2022. The drug’s popularity for weight loss could lead to more claims and lawsuits.

Do I Qualify for

Ozempic Lawsuit Compensation?
Free Case Review→

Multi-District Litigation (MDL) Updates for Ozempic

In December 2024, the existing Ozempic MDL was expanded to include claims involving Saxenda, another Novo Nordisk drug. Saxenda is the brand name of liraglutide, a GLP-1 agonist similar to semaglutide. While Ozempic is FDA-approved to treat Type II diabetes, Saxenda is approved for weight management even in non-diabetics.

In November 2024, the MDL took a pivotal turn. More claims alleged that Novo Nordisk didn’t just fail to warn patients of the gastrointestinal dangers of Ozempic — it also knew the risks and actively downplayed them to ensure more people would take the drug. As of November 2026, MDL No. 3163 had 278 pending cases.

The Ozempic lawsuits allege the drug causes severe gastroparesis, ileus, and intestinal blockage.

Here's a detailed look at the symptoms associated with each of these conditions:

Gastroparesis

Gastroparesis is a condition that affects the normal spontaneous movement of the muscles (called motility) in your stomach. It leads to delayed food emptying from the stomach into the small intestine.

Symptoms of Ozempic-induced gastroparesis can include the following:

  • Nausea and Vomiting: The vomit may contain undigested food.
  • Early Satiety: Patients may feel full sooner while eating.
  • Abdominal Bloating: The stomach may visibly expand (distended).
  • Abdominal Pain: Discomfort or pain can be widespread or localized.
  • Heartburn or Gastroesophageal Reflux: Patients feel a burning sensation in the chest.
  • Difficulty Managing Diabetes: Blood sugar surges and drops may become more dramatic, making it challenging to assess sugar levels.
  • Lack of Appetite: While seemingly ideal for weight loss, this symptom can cause malnutrition over time.

Notably, in many cases, gastroparesis is permanent. Even if you stop taking Ozempic, you may still suffer from this debilitating condition.

Ileus

Ileus refers to the temporary and often painful cessation of regular bowel contractions. It leads to a buildup of intestinal contents and potential blockage.

Symptoms of ileus due to Ozempic use can include the following:

  • Abdominal Distention: Swelling or enlargement of the abdomen
  • Pain and Cramping: Often spread out and not localized to one specific area
  • Nausea and Vomiting: Vomiting may include bile or fecal matter in severe cases
  • Inability to Pass Stool or Gas: Signifying a blockage in the intestines
  • Lack of Appetite: Due to discomfort and swelling

Intestinal Blockage

Intestinal blockage — also called bowel obstruction — occurs when something blocks the intestines, preventing the normal passage of contents through the digestive tract.

Symptoms of intestinal blockage linked to Ozempic can include the following:

  • Severe abdominal pain
  • Vomiting
  • Abdominal distension
  • Constipation or inability to pass gas
  • Diarrhea
  • Rapid heart rate and dehydration

These symptoms can be severe and debilitating and affect your quality of life and overall health. Although intestinal blockage was not originally listed on Ozempic’s label, the FDA required the addition of ileus to the label in September 2023. On October 14, 2025, it added intestinal obstruction to the side effects that people reported once the medication reached the public.

Do I Qualify for

Ozempic Lawsuit Compensation?
Free Case Review→

Why Are People Filing Ozempic Lawsuits?

The people filing lawsuits aren’t those who simply faced short-term bouts of gastrointestinal distress; they have suffered chronic — and sometimes even permanent — debilitating conditions. These conditions seriously damage quality of life and often lead to astronomical medical bills and lost income by rendering people unable to work.

Who Can File an Ozempic Lawsuit?

You might be eligible to file a lawsuit if you were prescribed Ozempic and experienced any of the following symptoms:

  • Ileus
  • Intestinal blockage
  • Gastroparesis (stomach paralysis), confirmed by a professionally done gastric emptying test
  • Problems with your gallbladder
  • Non-arteritic anterior ischemic optic neuropathy (NAAION)
  • Other serious problems

However, you might not qualify if you had a surgical weight loss procedure before taking Ozempic. The only way to know for sure whether you meet the criteria for joining the lawsuit or not is by consulting with an attorney who handles cases involving dangerous drugs.

Time Limits for Filing

All states have time limits to file lawsuits called a statute of limitations. The deadline varies widely from state to state.

For example, Kentucky provides one of the shortest time limits at just one year after an injury. However, the personal injury statute of limitations in California is more typical, giving injured people two years to file product liability cases.

Most states reduce the harshness of this deadline with an exception called the “discovery rule.” Under this legal doctrine, the time begins running when the plaintiff discovers their injury or reasonably should discover their injury.

States may also pause the running of the deadline in certain circumstances. For example, anyone unable to file a lawsuit due to their age or incapacity may have their deadline postponed. Thus, the time for a 17-year-old experiencing gastroparesis due to Ozempic might not start until they turn 18.

If a plaintiff misses the deadline without a legally recognized excuse, the judge must dismiss their case. As a result, the victim will be forever barred from seeking compensation for their injuries.

Therefore, you should speak to an attorney promptly upon discovering your GLP-1-related injury or disease for your state’s specific deadline and what you need to do to avoid it.

Do I Qualify for

Ozempic Lawsuit Compensation?
Free Case Review→

Key Factors That Could Influence Your Ozempic Settlement

Predicting Ozempic lawsuit settlement amounts is difficult because so much of the calculation depends on factors unique to the plaintiff. A victim who experienced bowel pain might prove a few thousand dollars in losses, while someone else might prove hundreds of thousands of dollars in losses because they had their gallbladder removed. The compensation for these losses is called compensatory damages. Ozempic cases may result in varied compensation depending on each plaintiff’s medical impact and documented losses.

Complicating the prediction even further is the role of punitive damages. Many of the headline-grabbing jury awards on past dangerous product lawsuits included tens or even hundreds of millions of dollars in punitive damages. Unlike compensatory damages, which are calculated based on the losses of the plaintiff, the calculation of punitive damages is based on the egregiousness of the defendant’s conduct.

Punitive damages punish bad actors. These damages warn other companies not to engage in dangerous or dishonest conduct. Some grounds for imposing punitive damages in other mass tort cases include the following:

  • Failing to warn consumers about known risks
  • Concealing the dangers of the product from regulators
  • Misleading the public about safety in its marketing materials
  • Paying “experts” to muddy the waters by publishing counter-articles

Initially, no one alleged that Novo Nordisk had engaged in any of this behavior. However, later lawsuits have claimed that Novo Nordisk failed to warn customers of Ozempic’s dangerous side effects and deliberately downplayed the risks in marketing campaigns. Both are common tactics of companies knowingly selling dangerous drugs.

The FDA has faulted Novo Nordisk as well. As stated in a warning letter on September 9, 2025, the agency found that an ABC primetime Oprah special on these weight loss drugs was misleading or false. It found that the special gave an inaccurate impression of Wegovy, Ozempic and Victoza.

In another letter, this one sent on March 5, 2026, the FDA stated that some serious side effect reports for medications and products containing semaglutide did not reach the agency on time or at all.

How Much Is the Ozempic Lawsuit Going to Pay Out?

While specific Ozempic lawsuit payouts available can vary based on individual circumstances and the lawsuit’s jurisdiction, common categories of damages sought in Ozempic settlements include the following:

Medical Expenses

Medical expenses include compensation for past, present, and future medical costs arising from the side effects or injuries alleged to have been caused by Ozempic. That includes hospital stays, medications, surgeries, and necessary long-term care or rehabilitation.

  • Ozempic allegedly causes:
  • Chronic vomiting
  • Gastrointestinal or stomach pain
  • Intestinal blockage or obstruction
  • Intestinal or stomach paralysis
  • Pancreatitis

These medical conditions can require:

  • Emergency room visits
  • Hospitalization
  • Gallbladder removal surgery

Every victim will incur different medical expenses depending on their symptoms and the treatment they receive. For example, gallbladder removal surgery costs between $5,000 and $17,000. This wide range depends on many factors unique to the patient, as well as other factors like the patient’s insurance company and any complications that arise.

Lost Wages and Earning Capacity

An Ozempic lawsuit payout may include lost wages if a plaintiff took time away from work to recover. Those suffering long-term impacts on their ability to work or earn a living may receive damages for lost earning capacity.

The loss amount depends on two primary factors: wages and recovery time. Victims who earn more will have more significant income losses. Similarly, victims who require more extensive treatment will miss more work. For example, the recovery time from gallbladder removal could run anywhere from one to six weeks.

Pain and Suffering

This category covers the physical pain and emotional distress suffered as a result of taking Ozempic. It can include compensation for enduring physical discomfort, mental anguish, loss of enjoyment of life, and the condition's impact on overall well-being.

Painful gastric problems can erode the quality of life. It can cause sleep deprivation and impact long-term health. Losing a gallbladder, for example, means losing vital functions that produce lifelong symptoms.

Unfortunately, pain and suffering damages are unpredictable. Jurors have considerable discretion in deciding how much to award for these losses, depending on the severity and impacts of the injury.

Punitive Damages

Sometimes, a jury may award punitive damages if the drug manufacturer was particularly egregious or reckless.

Legal Fees and Costs

Plaintiffs can seek reimbursement for the legal expenses incurred while pursuing an Ozempic settlement, including attorney fees, court costs, and expenses related to gathering evidence and expert testimony.

Loss of Consortium

Severe personal injuries may damage relationships with spouses or partners. Called “loss of consortium,” these damages acknowledge the damage to companionship, affection, and sexual relations.

Loss of consortium is usually a cause of action filed by an affected partner. Plaintiffs can also claim it if they face emotional or physical distress by their injury’s impacts on their relationship.

Are you eligible to file a lawsuit against Ozempic? Ready to seek compensation? ConsumerShield is prepared to connect you with an attorney who can help you.

Do I Qualify for

Ozempic Lawsuit Compensation?
Free Case Review→

Ozempic Lawsuit Knowledge Base

Frequently Asked Questions

  • No. Claims are handled in two federal MDLs: MDL No. 3094 for bowel and stomach injuries, and MDL No. 3163 for NAION vision loss. In an MDL, people can pursue individual settlements and verdicts instead of a share of a class settlement.

  • No. There have been no settlements in either MDL and no publicly reported settlement amounts. Neither MDL has a trial date.

  • Each state sets its own deadline. Kentucky allows one year after an injury, while California allows two years. Many states start the clock when you discover the injury, but you should speak to an attorney promptly.

More About Ozempic Lawsuit